Vudalimab (XmAb20717)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Vudalimab (XmAb20717), covering 2025-02-07 to 2025-02-07. Get the full timeline:
Most recent: Clinical Trial Update: A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies [Phase 2]